<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28975137</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2329-048X</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><PubDate><Year>2017</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Child neurology open</Title><ISOAbbreviation>Child Neurol Open</ISOAbbreviation></Journal><ArticleTitle>Rapid Resolution of Enterovirus 71-Associated Opsoclonus Myoclonus Syndrome on Intravenous Immunoglobulin.</ArticleTitle><Pagination><StartPage>2329048X17733215</StartPage><MedlinePgn>2329048X17733215</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2329048X17733215</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/2329048X17733215</ELocationID><Abstract><AbstractText>Nonparaneoplastic opsoclonus-myoclonus ataxia syndrome is a rare neuroinflammatory condition featured by opsoclonus, myoclonus, ataxia, and cognitive behavioral disturbance. The authors report an observation of enterovirus 71-associated opsoclonus-myoclonus ataxia syndrome evolving toward full recovery on intravenous intravenous immunoglobulin (IG) treatment. Based on this case report, enterovirus 71 should be added to the list of infectious agents likely involved in opsoclonus-myoclonus ataxia syndrome, including the emerging subgroup of opsoclonus-myoclonus ataxia syndrome recovering without aggressive or prolonged immunosuppressive intervention. Further studies are mandatory to define the precise role, incidence, treatment, and outcome of enterovirus 71 and other infectious agents in benign forms of opsoclonus-myoclonus ataxia syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sahly</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Child Neurology, Department of Pediatrics, Montreal Children's Hospital, McGill University, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauquelin</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Child Neurology, Department of Pediatrics, Montreal Children's Hospital, McGill University, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe9;bire</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Child Neurology, Department of Pediatrics, Montreal Children's Hospital, McGill University, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Child Neurol Open</MedlineTA><NlmUniqueID>101691975</NlmUniqueID><ISSNLinking>2329-048X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cerebellitis</Keyword><Keyword MajorTopicYN="N">Glucocorticoids</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Paraneoplasic Syndrome</Keyword></KeywordList><CoiStatement>Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>9</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28975137</ArticleId><ArticleId IdType="pmc">PMC5613794</ArticleId><ArticleId IdType="doi">10.1177/2329048X17733215</ArticleId><ArticleId IdType="pii">10.1177_2329048X17733215</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armangu&#xe9; T, Sabater L, Torres-Vega E, et al. Clinical and immunological features of opsoclonus-myoclonus syndrome in the era of neuronal cell surface antibodies. JAMA Neurol. 2016;73(4):417&#x2013;424. doi:10.1001/jamaneurol.2015.4607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5823978</ArticleId><ArticleId IdType="pubmed">26856612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bataller L, Graus F, Saiz A, Vilchez JJ; Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain. 2001;124(pt 2):437&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pubmed">11157570</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis. 2001;32(2):236&#x2013;242. doi:10.1086/318454.</Citation><ArticleIdList><ArticleId IdType="pubmed">11170913</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabarki B, Palmer P, Lebon P, S&#xe9;bire G. Spontaneous recovery of opsoclonus-myoclonus syndrome caused by enterovirus infection. J Neurol Neurosurg Psychiatr. 1998;64(3):406&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2170003</ArticleId><ArticleId IdType="pubmed">9527164</ArticleId></ArticleIdList></Reference><Reference><Citation>Ki Pang K, Lynch BJ, Osborne JP, Pike MG. Dancing eye syndrome associated with spontaneous recovery and normal neurodevelopment. Eur J Paediatr Neurol. 2010;14(2):178&#x2013;181. doi:10.1016/j.ejpn.2009.04.011.</Citation><ArticleIdList><ArticleId IdType="pubmed">19541513</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai J-D, Tsai HJ, Lin T-H, Chang Y-Y, Yang S-H, Kuo H-T. Comparison of the detection rates of RT-PCR and virus culture using a combination of specimens from multiple sites for enterovirus-associated encephalomyelitis during enterovirus 71 epidemic. Jpn J Infect Dis. 2014;67(5):333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">25241681</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778&#x2013;790. doi:10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell WG, Wooten AA, O&#x2019;Neil SH, Rodriguez JG, Cruz RE, Wittern R. Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS). J Child Neurol. 2015;30(8):976&#x2013;982. doi:10.1177/0883073814549581.</Citation><ArticleIdList><ArticleId IdType="pubmed">25342308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G, Wang J, Yao G, Shi B. Efficacy of high-dose methylprednisolone pulse therapy in the treatment of enterovirus 71 encephalitis. Pak J Pharm Sci. 2016;29(4 suppl):1421&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pubmed">27592493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, He F, Wan J, et al. Glucocorticoid and pyrazolone treatment of acute fever is a risk factor for critical and life-threatening human enterovirus 71 infection during an outbreak in China, 2008. Pediatr Infect Dis J. 2010;29(6):524&#x2013;529. doi:10.1097/INF.0b013e3181cdd178.</Citation><ArticleIdList><ArticleId IdType="pubmed">20104199</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen F-H, Shen T-J, Chang T-M, Su I-J, Chen S-H. Early dexamethasone treatment exacerbates enterovirus 71 infection in mice. Virology. 2014;464-465:218&#x2013;227. doi:10.1016/j.virol.2014.07.021.</Citation><ArticleIdList><ArticleId IdType="pubmed">25104614</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>